Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1127499

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nusinersen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has held with (a) NICE, (b) NHS England and (c) Biogen on a Managed Access Agreement for SMA treatment Spinraza.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	256254
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p> </p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE’s Appraisal Committee’s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256255 question first answered 29/05/2019 10:38:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1538 label Biography information for Rosie Cooper

1127500

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March 2019.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	256255
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p> </p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE’s Appraisal Committee’s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256254 question first answered 29/05/2019 10:38:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1538 label Biography information for Rosie Cooper

1126507

registered interest
date	14/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Members: Correspondence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he holds information on when the hon. Member for West Lancashire will receive a response to correspondence sent to Lancashire Care Foundation Trust on 14 March 2018 on mental health care.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	254165
answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>NHS Improvement has advised that the Trust responded to the hon. Member’s letter of 14 March 2019 on 17 May 2019.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 21/05/2019 11:09:33 answering member 1585 label Biography information for Stephen Hammond
tabling member	1538 label Biography information for Rosie Cooper